ATE474589T1 - Angiogene peptide und ihre verwendungen - Google Patents

Angiogene peptide und ihre verwendungen

Info

Publication number
ATE474589T1
ATE474589T1 AT04791852T AT04791852T ATE474589T1 AT E474589 T1 ATE474589 T1 AT E474589T1 AT 04791852 T AT04791852 T AT 04791852T AT 04791852 T AT04791852 T AT 04791852T AT E474589 T1 ATE474589 T1 AT E474589T1
Authority
AT
Austria
Prior art keywords
angiogenic peptides
peptide
peptides
amino acid
angiogenic
Prior art date
Application number
AT04791852T
Other languages
English (en)
Inventor
Britta Hardy
Alexander Battler
Annat Raiter
Ran Kornowski
Chana Weiss
Original Assignee
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ramot filed Critical Univ Ramot
Application granted granted Critical
Publication of ATE474589T1 publication Critical patent/ATE474589T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
AT04791852T 2003-10-29 2004-10-28 Angiogene peptide und ihre verwendungen ATE474589T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51489503P 2003-10-29 2003-10-29
US55855804P 2004-04-02 2004-04-02
PCT/IL2004/000992 WO2005039616A1 (en) 2003-10-29 2004-10-28 Angiogenic peptides and uses thereof

Publications (1)

Publication Number Publication Date
ATE474589T1 true ATE474589T1 (de) 2010-08-15

Family

ID=34527062

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04791852T ATE474589T1 (de) 2003-10-29 2004-10-28 Angiogene peptide und ihre verwendungen

Country Status (6)

Country Link
US (2) US7473682B2 (de)
EP (1) EP1677813B1 (de)
JP (1) JP2008500015A (de)
AT (1) ATE474589T1 (de)
DE (1) DE602004028266D1 (de)
WO (1) WO2005039616A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473682B2 (en) * 2003-10-29 2009-01-06 Ramot At Tel Aviv University Ltd. Angiogenic peptides and uses thereof
US7691396B2 (en) * 2005-06-15 2010-04-06 The Ohio State University Research Foundation Chimeric peptides comprising HER-2 B-cell epitopes and measles virus fusion protein T-cell epitopes
DE102005031755B9 (de) * 2005-07-01 2010-04-08 Technische Universität Dresden Salmonella spp. bindende Peptide, dafür kodierende Nukleinsäuren, deren Verwendungen und Verfahren und Kits zur Anreicherung, Immobilisierung und zum Nachweis von Salmonella spp.
CN101319008B (zh) * 2005-09-27 2010-12-01 南开大学 与肿瘤转移细胞特异性结合的多肽及其应用
WO2008047370A2 (en) 2006-10-19 2008-04-24 Ramot At Tel Aviv University Ltd. Compositions and methods for inducing angiogenesis
WO2010052715A2 (en) * 2008-11-07 2010-05-14 Ramot At Tel Aviv University Ltd. Devices and methods for local treatment of cardiovascular diseases
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
EP2385057A1 (de) * 2010-05-05 2011-11-09 Centre National de la Recherche Scientifique Peptidderivate zur Biofunktionalisierung von Siliciumsubstraten und deren Anwendungen
US10329327B2 (en) 2010-12-06 2019-06-25 Massachusetts Institute Of Technology Tricalcium phosphate binding peptides and uses thereof
DE102011003944A1 (de) 2011-02-10 2012-08-16 Oxprotect Gmbh Detektion und Entfernung von missgefalteten Proteinen/Peptiden
JP2022520139A (ja) 2018-10-12 2022-03-29 セラダプティブ インク β－リン酸三カルシウム結合配列を含むポリペプチドとその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638911B1 (en) * 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
EP1136082A1 (de) 2000-03-24 2001-09-26 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Lokalen Arzneistoffabgabe
AU7785401A (en) 2000-06-29 2002-01-14 Long Island Jewish Res Inst Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
US20030113714A1 (en) * 2001-09-28 2003-06-19 Belcher Angela M. Biological control of nanoparticles
US7241732B2 (en) * 2001-09-20 2007-07-10 University Of Rochester Compositions and methods involved in bone growth
US20030166004A1 (en) 2001-11-01 2003-09-04 Jeno Gyuris Endothelial-cell binding peptides for diagnosis and therapy
AU2003213246A1 (en) * 2002-02-21 2003-09-09 University Of Virginia Patent Foundation Bone targeting peptides
US20030221931A1 (en) * 2002-02-28 2003-12-04 Steve Marsh Sliding device
US7473682B2 (en) * 2003-10-29 2009-01-06 Ramot At Tel Aviv University Ltd. Angiogenic peptides and uses thereof
US7531505B2 (en) * 2006-01-11 2009-05-12 Affinergy, Inc. Compositions and methods for promoting attachment of cells of endothelial cell lineage to medical devices
US20080047370A1 (en) * 2006-08-07 2008-02-28 Vickery James H Jr Sampling apparatus for constituents in natural gas lines
WO2008047370A2 (en) * 2006-10-19 2008-04-24 Ramot At Tel Aviv University Ltd. Compositions and methods for inducing angiogenesis

Also Published As

Publication number Publication date
US7473682B2 (en) 2009-01-06
WO2005039616A1 (en) 2005-05-06
JP2008500015A (ja) 2008-01-10
EP1677813B1 (de) 2010-07-21
US20070082849A1 (en) 2007-04-12
US20090163405A1 (en) 2009-06-25
DE602004028266D1 (de) 2010-09-02
EP1677813A1 (de) 2006-07-12

Similar Documents

Publication Publication Date Title
ATE280826T1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
RS52815B (sr) Vezivna sredstva koja inhibiraju miostatin
RS50966B (sr) Agonisti pyy i njihova upotreba
MX2010002001A (es) Peptido cdca1 y agente farmaceutico que comprende elmismo.
ATE368053T1 (de) Antimikrobielle peptide
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
MX2010002018A (es) Peptido de cdh3 y agente medicinal que comprende al mismo.
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
ATE495247T1 (de) Chromoprotein und fluoroproteine
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
CY1109946T1 (el) Τροποποιημενα πεπτιδια και η χρηση τους για τη θεραπεια αυτοανοσων νοσων
NZ591827A (en) Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject
DK1504036T3 (da) Toxinrelaterede fragmenter af antistoffer med antimikrobiel og antiviral aktivitet
ATE362769T1 (de) Lineare kationische peptide mit fungizider wirksamkeit
ATE414099T1 (de) Biologisch aktive peptide
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
GB0207644D0 (en) Peptides and their use
ATE521635T1 (de) Physiologisch wirksamer komplex mit tnf aktivität
SE9700301D0 (sv) New compound
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
ATE305478T1 (de) Topoisomerase-ii inhibitoren
DE60008749D1 (de) Therapeutische peptide aus untersequenzen von bpi
TW200611913A (en) Biologically active peptides (Ⅲ)
WO2004058812A3 (en) Ribose-phosphate pyrophosphokinase polypeptides and structures
DE60135971D1 (de) Mit wt1 interagierendes protein, wtip

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties